Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
59 studies found for:    Myasthenia Gravis
Show Display Options
RSS Create an RSS feed from your search for:
Myasthenia Gravis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
2 Active, not recruiting The Role of the Thymus in Myasthenia Gravis
Conditions: Myasthenia Gravis;   Thymoma
Intervention:
3 Terminated Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
4 Completed
Has Results
Efficacy of Methotrexate in Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate;   Other: Placebo
5 Recruiting Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Biological: CV-MG01;   Biological: Placebo
6 Recruiting Tissue Repository for Studies of Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: No interventions
7 Completed Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Intravenous ImmuneGlobulin
8 Active, not recruiting Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy;   Drug: prednisone
9 Terminated Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Subcutaneous immunoglobulins
10 Recruiting Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Condition: Myasthenia Gravis, Generalized
Interventions: Drug: Placebo;   Drug: CFZ533
11 Completed Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: eculizumab;   Drug: Placebo
12 Completed A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Tacrolimus capsule;   Drug: Placebo
13 Completed A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Condition: Refractory Myasthenia Gravis
Intervention: Drug: Rituximab (Rituxan)
14 Completed Mycophenolate Mofetil in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: mycophenolate mofetil
15 Recruiting Exercise for Stable Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Other: Exercise
16 Active, not recruiting Phase II Trial of Rituximab In Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Rituximab;   Drug: Placebo
17 Active, not recruiting Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Drug: Prednisone - Azathioprine
18 Recruiting Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Behavioral: Physical exercise programme using a rowing machine
19 Completed Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
Condition: Generalized Myasthenia Gravis
Interventions: Biological: GB-0998 (Intravenous immunoglobulin);   Procedure: Plasmapheresis
20 Unknown  Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Mycophenolic acid;   Drug: AZA

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years